KR20120084298A - 펩티드 제거제 - Google Patents

펩티드 제거제 Download PDF

Info

Publication number
KR20120084298A
KR20120084298A KR1020127010173A KR20127010173A KR20120084298A KR 20120084298 A KR20120084298 A KR 20120084298A KR 1020127010173 A KR1020127010173 A KR 1020127010173A KR 20127010173 A KR20127010173 A KR 20127010173A KR 20120084298 A KR20120084298 A KR 20120084298A
Authority
KR
South Korea
Prior art keywords
peptide
binding
enzyme
peptides
cpg2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127010173A
Other languages
English (en)
Korean (ko)
Inventor
폴 제임스 데이비스
제임스 알렉산더 슈하우텐
Original Assignee
몰로직 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 몰로직 리미티드 filed Critical 몰로직 리미티드
Publication of KR20120084298A publication Critical patent/KR20120084298A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020127010173A 2009-09-23 2010-09-23 펩티드 제거제 Withdrawn KR20120084298A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0916749.5 2009-09-23
GBGB0916749.5A GB0916749D0 (en) 2009-09-23 2009-09-23 Peptide cleaning agents

Publications (1)

Publication Number Publication Date
KR20120084298A true KR20120084298A (ko) 2012-07-27

Family

ID=41327500

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127010173A Withdrawn KR20120084298A (ko) 2009-09-23 2010-09-23 펩티드 제거제

Country Status (16)

Country Link
US (1) US8846861B2 (https=)
EP (1) EP2470216A1 (https=)
JP (1) JP2013505287A (https=)
KR (1) KR20120084298A (https=)
CN (1) CN102665768B (https=)
AU (1) AU2010299643B2 (https=)
BR (1) BR112012006389A2 (https=)
CA (1) CA2774081A1 (https=)
GB (1) GB0916749D0 (https=)
IL (1) IL218713A0 (https=)
IN (1) IN2012DN02241A (https=)
MX (1) MX2012003565A (https=)
NZ (1) NZ598802A (https=)
SG (1) SG179015A1 (https=)
WO (1) WO2011036457A1 (https=)
ZA (1) ZA201201527B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2435510A (en) 2006-02-23 2007-08-29 Mologic Ltd Enzyme detection product and methods
WO2012021512A2 (en) 2010-08-10 2012-02-16 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
KR102717969B1 (ko) 2014-02-21 2024-10-15 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) 글리코타겟팅 치료제
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности
IL294515A (en) 2020-01-31 2022-09-01 Avilar Therapeutics Inc Compounds bind asgpr to degrade extracellular proteins
WO2022235699A2 (en) 2021-05-03 2022-11-10 Avilar Therapeutics, Inc. Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075010A (en) 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
US20030068322A1 (en) 1988-04-18 2003-04-10 Immunomedics, Inc. Methods of antibody-directed enzyme-prodrug therapy
EP0538268A4 (en) 1990-05-11 1993-05-12 The University Of Connecticut Targeted protection from cytotoxins
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US6172045B1 (en) * 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
EP0837696B1 (en) 1995-06-07 2010-02-24 Immunomedics, Inc. Improved delivery of diagnostic and therapeutic agents to a target site
GB9524942D0 (en) * 1995-12-06 1996-02-07 Aepact Ltd Drug therapy
AU744444B2 (en) * 1996-10-31 2002-02-21 Karo Bio Ab Identification of drugs using complementary combinatorial libraries
GB9624993D0 (en) * 1996-11-30 1997-01-15 Aepact Ltd Tumour therapy
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US6465612B1 (en) * 1998-09-23 2002-10-15 The Regents Of The University Of California Synthetic peptides, conjugation reagents and methods
JP2004535560A (ja) * 2001-04-20 2004-11-25 ザ ユニヴァーシティ オブ ジョージア リサーチファウンデーション， インク． 活性部位不活性化因子
EP1929073A4 (en) * 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
ATE514711T1 (de) 2007-10-16 2011-07-15 Toscana Biomarkers S R L Galactosylierte peptide, deren zubereitung und verwendung zur diagnose von autoimmunerkrankungen

Also Published As

Publication number Publication date
JP2013505287A (ja) 2013-02-14
CN102665768A (zh) 2012-09-12
AU2010299643A1 (en) 2012-03-22
SG179015A1 (en) 2012-04-27
IN2012DN02241A (https=) 2015-08-21
AU2010299643B2 (en) 2014-06-26
US20130053543A1 (en) 2013-02-28
WO2011036457A1 (en) 2011-03-31
BR112012006389A2 (pt) 2016-11-22
MX2012003565A (es) 2012-08-03
EP2470216A1 (en) 2012-07-04
GB0916749D0 (en) 2009-11-04
CA2774081A1 (en) 2011-03-31
CN102665768B (zh) 2015-01-21
US8846861B2 (en) 2014-09-30
NZ598802A (en) 2013-10-25
IL218713A0 (en) 2012-05-31
ZA201201527B (en) 2013-05-29

Similar Documents

Publication Publication Date Title
KR20120084298A (ko) 펩티드 제거제
JP7417432B2 (ja) 新規リンカー、その製造方法およびその応用
JP7291395B2 (ja) ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾
KR102746415B1 (ko) Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
ES2864013T3 (es) Conjugados de fármaco y anticuerpo activable anti-CD71 y métodos de uso de los mismos
ES2855998T3 (es) Etiqueta transglutamina para bioconjugación específica de sitio eficiente
AU784285B2 (en) Methods and compositions for prolonging elimination half-times of bioactive compounds
AU2015370918B2 (en) Binding protein drug conjugates comprising anthracycline derivatives
AU2016225810A1 (en) Modified Antibody Compositions, Methods of Making and Using Thereof
JP2012511033A5 (https=)
US20180339043A1 (en) Modified antibodies
CA3033614A1 (en) Tgf-.beta. antagonist conjugates
JP5677454B2 (ja) 細胞内ターゲット結合用二座ペプチドバインダー
WO2024150174A1 (en) Conditionally activated immunocytokines and methods of use
Ucar et al. A new radio-theranostic agent candidate: Synthesis and analysis of (ADH-1) c-EDTA conjugate
JP2026501108A (ja) ソルチリンの標的化
KR20250089528A (ko) 신규한 napi2b 항체를 함유하는 신규한 항체 약물 접합체, 치료 방법 및 이의 용도
van Baal Peptides and proteins in dendritic assemblies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120420

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid